V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 180001626 | 180004214 | null | null | null | 2021-07-15 | 2021-10-14 | Cyclophosphamide + Topotecan | null | null | CISPLATIN + PACLITAXEL | 100413368 |
| 180003267 | 180004219 | null | null | null | 2017-07-27 | 2017-08-06 | NB 13 cis-RA (Isotretinoin) | null | null | DOXORUBICIN + IFOSFAMIDE | 100452690 |
| 180003594 | 180004222 | null | null | null | 2017-09-24 | 2017-11-07 | AFATINIB | null | null | NB HRNBL-1 ISOTRETINOIN | 101446736 |
| 180003609 | 180004223 | null | null | null | 2022-02-13 | 2022-02-13 | LENVATINIB | null | null | ETOPOSIDE | 100996924 |
| 180004419 | 180004227 | null | null | null | 2020-04-22 | 2020-05-19 | NB HRNBL-1 TVD | null | null | PACLITAXEL | 101263786 |
| 180004943 | 180004230 | null | null | null | null | 2018-12-22 | CAPECITABINE + TEMOZOLOMIDE | null | null | DINUTUXIMAB BETA | 100113751 |
| 180005449 | 180004233 | null | null | null | 2021-12-13 | 2021-12-19 | Sorafenib | null | null | NB HRNBL-1 ISOTRETINOIN | 100345088 |
| 180006703 | 180004239 | null | null | null | null | 2018-08-29 | Trastuzumab emtansine (Kadcyla) M | null | null | LENVATINIB | 101684845 |
| 180007273 | 180004242 | null | null | null | null | 2019-06-25 | ALL UKALL2011 Consolidation A | null | null | LENVATINIB | 100541864 |
| 180007391 | 180004244 | null | null | null | null | 2021-04-08 | Trial Unspecified | null | null | NB HRNBL-1 COJEC IND COURSE C | 100166188 |
| 180008440 | 180004248 | null | null | null | null | 2020-08-07 | NB HRNBL-1 Isotretinoin | null | null | CARBOPLATIN + PACLITAXEL | 101358012 |
| 180012028 | 180004261 | null | null | null | 2017-10-11 | 2017-10-12 | Dinutuximab Beta | null | null | CAPECITABINE | 101510187 |
| 180000148 | 180004267 | null | null | null | 2021-11-07 | 2021-11-17 | Capecitabine | null | null | PACLITAXEL | 101619404 |
| 180000098 | 180004271 | 1.75 | null | null | null | 2022-02-10 | Carboplatin + Paclitaxel (3 weekly) | null | null | NB HRNBL-1 ISOTRETINOIN | 101425257 |
| 180003921 | 180004279 | null | null | null | 2021-04-14 | 2021-05-12 | Mitotane 5.5 - 10g | null | null | EVEROLIMUS + EXEMESTANE | 100667986 |
| 180004419 | 180004281 | null | null | null | null | 2020-06-06 | Trial Unspecified | null | null | DOXORUBICIN + IFOSFAMIDE | 101263786 |
| 180004943 | 180004283 | null | null | null | 2019-01-18 | 2019-02-07 | Trial Unspecified | null | null | NB HRNBL-1 ISOTRETINOIN | 100113751 |
| 180005449 | 180004285 | null | null | null | 2021-12-28 | 2022-01-17 | Oxaliplatin + Modified de Gramont | null | null | LENVATINIB | 100345088 |
| 180007391 | 180004291 | 0 | 18 | Neo-adjuvant (N) | 2021-05-06 | 2021-05-06 | EW Rel rEECur Topotecan/Cyclophosphamide | 01 | null | LENVATINIB | 100166188 |
| 180009311 | 180004296 | null | null | null | null | 2019-07-26 | NB Low/Intermed risk guidelines CADO | null | null | DINUTUXIMAB BETA | 100085321 |
| 180010221 | 180004299 | null | null | null | 2014-12-15 | 2016-08-31 | Paclitaxel 7 day | null | null | DABRAFENIB + TRAMETINIB | 100590552 |
| 180010452 | 180004300 | null | null | null | 2021-01-15 | 2021-10-18 | Cisplatin + Pemetrexed | null | null | NOT MATCHED | 100870125 |
| 180012155 | 180004306 | null | null | null | null | 2018-07-09 | NB HRNBL-1 BUMEL MAT | 2 | null | NB HRNBL-1 COJEC IND COURSE C | 100361650 |
| 180003609 | 180004315 | null | null | null | null | 2022-05-24 | EDP + MITOTANE | null | null | PACLITAXEL | 100996924 |
| 180004076 | 180004317 | 1.78 | null | null | null | 2021-07-19 | CARBOPLATIN + PACLITAXEL | null | null | CARBOPLATIN + PACLITAXEL | 100554776 |
| 180006703 | 180004324 | null | null | null | 2018-12-02 | 2018-12-09 | null | null | null | CABOZANTINIB | 101684845 |
| 180007162 | 180004325 | null | null | null | null | 2021-06-15 | NB HRNBL-1 ch14.18/CHO only (trial) | null | null | NB RELAPSE TEMOZOLOMIDE/ TOPOTECAN | 101322782 |
| 180009311 | 180004328 | null | null | null | 2018-07-29 | 2019-08-12 | LENVATINIB | null | null | FLUOROURACIL + OXALIPLATIN | 100085321 |
| 180012063 | 180004335 | null | null | null | 2021-09-12 | 2021-09-12 | null | null | null | NB HRNBL-1 ISOTRETINOIN | 101472984 |
| 180003267 | 180004337 | null | null | null | 2017-07-11 | 2017-07-11 | Abiraterone | 02 | null | NOT MATCHED | 100452690 |
| 180004943 | 180004341 | null | null | null | 2019-09-10 | 2019-09-20 | CABOZANTINIB | null | null | CISPLATIN | 100113751 |
| 180009311 | 180004344 | null | null | null | null | 2019-06-20 | CABOZANTINIB | null | null | CARBOPLATIN + PEMETREXED | 100085321 |
| 180009623 | 180004345 | 1.64 | null | null | 2019-08-16 | 2019-08-21 | Trial Unspecified | null | null | LENVATINIB | 100674591 |
| 180009685 | 180004346 | null | null | null | 2019-01-22 | 2019-02-13 | NB HRNBL-1 COJEC Ind COURSE C | null | null | NOT MATCHED | 101809073 |
| 180010221 | 180004347 | null | null | null | null | 2016-10-24 | NB Rel CCLG guidelines Cyclo-Topotecan | null | null | TRIAL UNSPECIFIED | 100590552 |
| 180010672 | 180004348 | 1.79 | null | null | null | 2022-04-21 | NB Rel CCLG guidelines Cyclo-Topotecan | null | null | VANDETANIB | 100230100 |
| 180012063 | 180004349 | null | null | null | 2021-07-02 | 2021-10-08 | Cetuximab + Encorafenib | null | null | NB HRNBL-1 ISOTRETINOIN | 101472984 |
| 180004943 | 180004354 | null | null | null | null | 2019-11-06 | Gemcitabine + Capecitabine | null | null | NB HRNBL-1 ISOTRETINOIN | 100113751 |
| 180004943 | 180004371 | null | null | null | null | 2020-01-30 | null | null | null | CABOZANTINIB | 100113751 |
| 180009623 | 180004373 | null | null | null | 2019-08-03 | 2019-08-19 | NB Rel CCLG guidelines Irin & Temoz | null | null | NB HRNBL-1 ISOTRETINOIN | 100674591 |
| 180009623 | 180004382 | 0.82 | null | null | 2019-07-16 | 2019-08-03 | CISPLATIN + DOX + ETOPOSIDE + MITOTANE | null | null | NB HRNBL-1 TVD | 100674591 |
| 190000001 | 190000001 | 1.68 | 89.1 | Palliative (P) | 2017-06-27 | 2017-07-16 | CARBOPLATIN + ETOPOSIDE | 02 | N | CARBOPLATIN + ETOPOSIDE | 100490860 |
| 190000031 | 190000005 | 0 | 88.5 | Neo-adjuvant (N) | 2016-02-24 | 2016-02-24 | STS Rhabdomyosarcoma RMS 2005 IVAVV | 02 | N | LUTETIUM-177 | 100695311 |
| 190000047 | 190000006 | 1.51 | 78.6 | Neo-adjuvant (N) | 2016-07-08 | 2016-07-08 | OST Euramos 1 Closed Trial - AP | N | N | CISPLATIN + RT | 101864298 |
| 190000058 | 190000007 | 1.67 | 95.5 | Curative (C) | 2017-09-26 | 2017-10-05 | EURAMOS TRIAL | 02 | N | GEMCITABINE | 101694014 |
| 190000059 | 190000008 | null | null | null | null | 2018-09-10 | EW EuroEwing 99 : VIDE | null | null | CISPLATIN + ETOPOSIDE | 101782564 |
| 190000086 | 190000012 | null | null | null | null | 2016-12-27 | Cisplatin 100 + RT(H&N) 1 day | null | null | CISPLATIN | 100724016 |
| 190000099 | 190000015 | null | null | null | null | 2017-05-17 | Cisplatin+Gemcitabine (gallbladder) | null | null | CISPLATIN + GEMCITABINE | 101631788 |
| 190000111 | 190000018 | null | null | null | null | 2016-08-07 | Cisplatin | null | null | CISPLATIN | 101518950 |
| 190000119 | 190000019 | 1.63 | 65.7 | null | 2017-12-26 | 2018-01-16 | Carboplatin + Etoposide iv&po | 02 | null | CARBOPLATIN + ETOPOSIDE | 100683804 |